Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company employs 12 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
RGC stock price ended at $26.72 on 水曜日, after rising 0.15%
On the latest trading day Feb 11, 2026, the stock price of RGC rose by 0.15%, climbing from $27.00 to $26.72. Throughout the session, the stock experienced a volatility of 5.47%, with prices fluctuating between a daily low of $25.80 and a high of $27.21. Alongside this price increase, trading volume also rose by 21.1K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 56.4K shares were traded, amounting to a market value of approximately $13.2B.